Business Context and Reporting Period
This Form 8-K is a current report filed by Imprimis Pharmaceuticals, Inc. (not Harrow, Inc.) on May 10, 2017. The filing serves to announce the company's financial results for the first quarter ended March 31, 2017. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet for the filing and does not contain specific financial data. Consequently, the following metrics are not available in this document:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt and Liquidity
Note: The filing text does not provide a clear value for any financial metric; these figures are located in the referenced Exhibit 99.1 press release, which is not included in the input.
Material Changes
The filing text does not disclose specific material changes versus the prior comparable period. It only confirms that a press release detailing the Q1 2017 results was issued.
Guidance, Outlook, and Risks
The document contains standard legal disclaimers regarding the information furnished under Item 2.02:
- The information is not deemed "filed" for purposes of Section 18 of the Exchange Act.
- The information is not incorporated by reference into other filings unless specifically stated.
- The company does not assume an obligation to update the information in the future.
No specific guidance, outlook, or risk factors are detailed in this text.
Investor Verification Checklist
- Verify the correct registrant name is Imprimis Pharmaceuticals, Inc., as the metadata request incorrectly listed "Harrow, Inc."
- Locate and review Exhibit 99.1 (the press release dated May 10, 2017) to obtain actual revenue, net loss, and cash position figures.
- Confirm the reporting period is the quarter ended March 31, 2017.
- Note that this 8-K filing itself contains no quantitative financial data.